Although targeted therapy—particularly vascular endothelial growth factor (VEGF) inhibitors—and immune checkpoint blockade have significantly improved prognosis in cancer patients, therapeutic resistance remains as a major challenge (2). This evidence concerns the gene VEGFA and cancer.